Selected research
Market Outlook & Growth Opportunities
Global Patient-Derived Disease Modeling Platform Market Outlook and Growth Opportunities 2026
Market perspective
The global Patient-Derived Disease Modeling Platform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Patient-Derived Disease Modeling Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Patient-Derived Disease Modeling Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Patient-Derived Disease Modeling Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Patient-Derived Disease Modeling Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Patient-Derived Disease Modeling Platform market include Evotec, Pharmaron, The Jackson Laboratory, Champions Oncology, ATCC, Molecular Devices, FUJIFILM Cellular Dynamics, REPROCELL and Ncardia, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Patient-Derived Disease Modeling Platform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Patient-Derived Disease Modeling Platform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Patient-Derived Disease Modeling Platform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Patient-Derived Disease Modeling Platform market.
Patient-Derived Disease Modeling Platform Segment by Company
Evotec
Pharmaron
The Jackson Laboratory
Champions Oncology
ATCC
Molecular Devices
FUJIFILM Cellular Dynamics
REPROCELL
Ncardia
Axol Bioscience
MIMETAS
Oncodesign Services
GemPharmatech
Shanghai Model Organisms Center
Medicilon
InnoSer
Certis Oncology Solutions
Curi Bio
Newcells Biotech
K2 Oncology
Pixlbio
Charles River Laboratories
Crown Bioscience
WuXi AppTec
Patient-Derived Disease Modeling Platform Segment by Type
Patient-Derived Primary Cell Models
Patient-Derived iPSC Models
Patient-Derived Organoid Models
Patient-Derived Tissue Explant Models
Patient-Derived Organ-on-a-Chip Models
Patient-Derived Xenograft Models
Patient-Derived Disease Modeling Platform Segment by Application
Disease Mechanism Research
Target Discovery and Validation
Drug Screening and Lead Optimization
Efficacy and Resistance Evaluation
Safety and Toxicology Assessment
Precision Medicine and Biomarker Research
Patient-Derived Disease Modeling Platform Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Patient-Derived Disease Modeling Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Patient-Derived Disease Modeling Platform key companies, revenue, market share, and recent developments.
3. To split the Patient-Derived Disease Modeling Platform breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Patient-Derived Disease Modeling Platform market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Patient-Derived Disease Modeling Platform significant trends, drivers, influence factors in global and regions.
6. To analyze Patient-Derived Disease Modeling Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Patient-Derived Disease Modeling Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Patient-Derived Disease Modeling Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Patient-Derived Disease Modeling Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Patient-Derived Disease Modeling Platform industry.
Chapter 3: Detailed analysis of Patient-Derived Disease Modeling Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Patient-Derived Disease Modeling Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Patient-Derived Disease Modeling Platform in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Patient-Derived Disease Modeling Platform Industry Trends
Table 2. Patient-Derived Disease Modeling Platform Industry Drivers
Table 3. Patient-Derived Disease Modeling Platform Industry Opportunities and Challenges
Table 4. Patient-Derived Disease Modeling Platform Industry Restraints
Table 5. Global Patient-Derived Disease Modeling Platform Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Patient-Derived Disease Modeling Platform Revenue Share by Company (2021-2026)
Table 7. Global Patient-Derived Disease Modeling Platform Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Patient-Derived Disease Modeling Platform Key Company Manufacturing Base & Headquarters
Table 9. Global Patient-Derived Disease Modeling Platform Company, Product Type & Application
Table 10. Global Patient-Derived Disease Modeling Platform Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Patient-Derived Disease Modeling Platform by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Patient-Derived Primary Cell Models
Table 15. Significant Companies of Patient-Derived iPSC Models
Table 16. Significant Companies of Patient-Derived Organoid Models
Table 17. Significant Companies of Patient-Derived Tissue Explant Models
Table 18. Significant Companies of Patient-Derived Organ-on-a-Chip Models
Table 19. Significant Companies of Patient-Derived Xenograft Models
Table 20. Global Patient-Derived Disease Modeling Platform Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 21. Global Patient-Derived Disease Modeling Platform Sales Value by Type (2021-2026) & (US$ Million)
Table 22. Global Patient-Derived Disease Modeling Platform Sales Value by Type (2027-2032) & (US$ Million)
Table 23. Global Patient-Derived Disease Modeling Platform Sales Value Share by Type (2021-2026)
Table 24. Global Patient-Derived Disease Modeling Platform Sales Value Share by Type (2027-2032)
Table 25. Significant Companies of Disease Mechanism Research
Table 26. Significant Companies of Target Discovery and Validation
Table 27. Significant Companies of Drug Screening and Lead Optimization
Table 28. Significant Companies of Efficacy and Resistance Evaluation
Table 29. Significant Companies of Safety and Toxicology Assessment
Table 30. Significant Companies of Precision Medicine and Biomarker Research
Table 31. Global Patient-Derived Disease Modeling Platform Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Patient-Derived Disease Modeling Platform Sales Value by Application (2021-2026) & (US$ Million)
Table 33. Global Patient-Derived Disease Modeling Platform Sales Value by Application (2027-2032) & (US$ Million)
Table 34. Global Patient-Derived Disease Modeling Platform Sales Value Share by Application (2021-2026)
Table 35. Global Patient-Derived Disease Modeling Platform Sales Value Share by Application (2027-2032)
Table 36. Global Patient-Derived Disease Modeling Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global Patient-Derived Disease Modeling Platform Sales Value by Region (2021-2026) & (US$ Million)
Table 38. Global Patient-Derived Disease Modeling Platform Sales Value Share by Region (2021-2026)
Table 39. Global Patient-Derived Disease Modeling Platform Sales Value by Region (2027-2032) & (US$ Million)
Table 40. Global Patient-Derived Disease Modeling Platform Sales Value Share by Region (2027-2032)
Table 41. Global Patient-Derived Disease Modeling Platform Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 42. Global Patient-Derived Disease Modeling Platform Sales Value by Country (2021-2026) & (US$ Million)
Table 43. Global Patient-Derived Disease Modeling Platform Sales Value Market Share by Country (2021-2026)
Table 44. Global Patient-Derived Disease Modeling Platform Sales Value by Country (2027-2032) & (US$ Million)
Table 45. Global Patient-Derived Disease Modeling Platform Sales Value Market Share by Country (2027-2032)
Table 46. Evotec Company Information
Table 47. Evotec Business Overview
Table 48. Evotec Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 49. Evotec Patient-Derived Disease Modeling Platform Product Portfolio
Table 50. Evotec Recent Development
Table 51. Pharmaron Company Information
Table 52. Pharmaron Business Overview
Table 53. Pharmaron Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 54. Pharmaron Patient-Derived Disease Modeling Platform Product Portfolio
Table 55. Pharmaron Recent Development
Table 56. The Jackson Laboratory Company Information
Table 57. The Jackson Laboratory Business Overview
Table 58. The Jackson Laboratory Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. The Jackson Laboratory Patient-Derived Disease Modeling Platform Product Portfolio
Table 60. The Jackson Laboratory Recent Development
Table 61. Champions Oncology Company Information
Table 62. Champions Oncology Business Overview
Table 63. Champions Oncology Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 64. Champions Oncology Patient-Derived Disease Modeling Platform Product Portfolio
Table 65. Champions Oncology Recent Development
Table 66. ATCC Company Information
Table 67. ATCC Business Overview
Table 68. ATCC Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. ATCC Patient-Derived Disease Modeling Platform Product Portfolio
Table 70. ATCC Recent Development
Table 71. Molecular Devices Company Information
Table 72. Molecular Devices Business Overview
Table 73. Molecular Devices Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. Molecular Devices Patient-Derived Disease Modeling Platform Product Portfolio
Table 75. Molecular Devices Recent Development
Table 76. FUJIFILM Cellular Dynamics Company Information
Table 77. FUJIFILM Cellular Dynamics Business Overview
Table 78. FUJIFILM Cellular Dynamics Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 79. FUJIFILM Cellular Dynamics Patient-Derived Disease Modeling Platform Product Portfolio
Table 80. FUJIFILM Cellular Dynamics Recent Development
Table 81. REPROCELL Company Information
Table 82. REPROCELL Business Overview
Table 83. REPROCELL Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 84. REPROCELL Patient-Derived Disease Modeling Platform Product Portfolio
Table 85. REPROCELL Recent Development
Table 86. Ncardia Company Information
Table 87. Ncardia Business Overview
Table 88. Ncardia Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Ncardia Patient-Derived Disease Modeling Platform Product Portfolio
Table 90. Ncardia Recent Development
Table 91. Axol Bioscience Company Information
Table 92. Axol Bioscience Business Overview
Table 93. Axol Bioscience Patient-Derived Disease Modeling Platform Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Axol Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
Table 95. Axol Bioscience Recent Development
Table 96. MIMETAS Company Information
Table 97. MIMETAS Business Overview
Table 98. MIMETAS Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 99. MIMETAS Patient-Derived Disease Modeling Platform Product Portfolio
Table 100. MIMETAS Recent Development
Table 101. Oncodesign Services Company Information
Table 102. Oncodesign Services Business Overview
Table 103. Oncodesign Services Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 104. Oncodesign Services Patient-Derived Disease Modeling Platform Product Portfolio
Table 105. Oncodesign Services Recent Development
Table 106. GemPharmatech Company Information
Table 107. GemPharmatech Business Overview
Table 108. GemPharmatech Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 109. GemPharmatech Patient-Derived Disease Modeling Platform Product Portfolio
Table 110. GemPharmatech Recent Development
Table 111. Shanghai Model Organisms Center Company Information
Table 112. Shanghai Model Organisms Center Business Overview
Table 113. Shanghai Model Organisms Center Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 114. Shanghai Model Organisms Center Patient-Derived Disease Modeling Platform Product Portfolio
Table 115. Shanghai Model Organisms Center Recent Development
Table 116. Medicilon Company Information
Table 117. Medicilon Business Overview
Table 118. Medicilon Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 119. Medicilon Patient-Derived Disease Modeling Platform Product Portfolio
Table 120. Medicilon Recent Development
Table 121. InnoSer Company Information
Table 122. InnoSer Business Overview
Table 123. InnoSer Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 124. InnoSer Patient-Derived Disease Modeling Platform Product Portfolio
Table 125. InnoSer Recent Development
Table 126. Certis Oncology Solutions Company Information
Table 127. Certis Oncology Solutions Business Overview
Table 128. Certis Oncology Solutions Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 129. Certis Oncology Solutions Patient-Derived Disease Modeling Platform Product Portfolio
Table 130. Certis Oncology Solutions Recent Development
Table 131. Curi Bio Company Information
Table 132. Curi Bio Business Overview
Table 133. Curi Bio Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 134. Curi Bio Patient-Derived Disease Modeling Platform Product Portfolio
Table 135. Curi Bio Recent Development
Table 136. Newcells Biotech Company Information
Table 137. Newcells Biotech Business Overview
Table 138. Newcells Biotech Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 139. Newcells Biotech Patient-Derived Disease Modeling Platform Product Portfolio
Table 140. Newcells Biotech Recent Development
Table 141. K2 Oncology Company Information
Table 142. K2 Oncology Business Overview
Table 143. K2 Oncology Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 144. K2 Oncology Patient-Derived Disease Modeling Platform Product Portfolio
Table 145. K2 Oncology Recent Development
Table 146. Pixlbio Company Information
Table 147. Pixlbio Business Overview
Table 148. Pixlbio Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 149. Pixlbio Patient-Derived Disease Modeling Platform Product Portfolio
Table 150. Pixlbio Recent Development
Table 151. Charles River Laboratories Company Information
Table 152. Charles River Laboratories Business Overview
Table 153. Charles River Laboratories Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 154. Charles River Laboratories Patient-Derived Disease Modeling Platform Product Portfolio
Table 155. Charles River Laboratories Recent Development
Table 156. Crown Bioscience Company Information
Table 157. Crown Bioscience Business Overview
Table 158. Crown Bioscience Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 159. Crown Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
Table 160. Crown Bioscience Recent Development
Table 161. WuXi AppTec Company Information
Table 162. WuXi AppTec Business Overview
Table 163. WuXi AppTec Patient-Derived Disease Modeling Platform Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 164. WuXi AppTec Patient-Derived Disease Modeling Platform Product Portfolio
Table 165. WuXi AppTec Recent Development
Table 166. Research Programs/Design for This Report
Table 167. Authors List of This Report
Table 168. Secondary Sources
Table 169. Primary Sources
List of Figures
Figure 1. Patient-Derived Disease Modeling Platform Product Image
Figure 2. Global Patient-Derived Disease Modeling Platform Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Patient-Derived Disease Modeling Platform Market Size (2021-2032) & (US$ Million)
Figure 4. Global Patient-Derived Disease Modeling Platform Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Patient-Derived Primary Cell Models Image
Figure 8. Patient-Derived iPSC Models Image
Figure 9. Patient-Derived Organoid Models Image
Figure 10. Patient-Derived Tissue Explant Models Image
Figure 11. Patient-Derived Organ-on-a-Chip Models Image
Figure 12. Patient-Derived Xenograft Models Image
Figure 13. Global Patient-Derived Disease Modeling Platform Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 14. Global Patient-Derived Disease Modeling Platform Sales Value Share 2021 VS 2025 VS 2032
Figure 15. Global Patient-Derived Disease Modeling Platform Sales Value Share by Type (2021-2032)
Figure 16. Disease Mechanism Research Image
Figure 17. Target Discovery and Validation Image
Figure 18. Drug Screening and Lead Optimization Image
Figure 19. Efficacy and Resistance Evaluation Image
Figure 20. Safety and Toxicology Assessment Image
Figure 21. Precision Medicine and Biomarker Research Image
Figure 22. Global Patient-Derived Disease Modeling Platform Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 23. Global Patient-Derived Disease Modeling Platform Sales Value Share 2021 VS 2025 VS 2032
Figure 24. Global Patient-Derived Disease Modeling Platform Sales Value Share by Application (2021-2032)
Figure 25. Global Patient-Derived Disease Modeling Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 26. Global Patient-Derived Disease Modeling Platform Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 27. North America Patient-Derived Disease Modeling Platform Sales Value (2021-2032) & (US$ Million)
Figure 28. North America Patient-Derived Disease Modeling Platform Sales Value Share by Country (%), 2025 VS 2032
Figure 29. Europe Patient-Derived Disease Modeling Platform Sales Value (2021-2032) & (US$ Million)
Figure 30. Europe Patient-Derived Disease Modeling Platform Sales Value Share by Country (%), 2025 VS 2032
Figure 31. Asia-Pacific Patient-Derived Disease Modeling Platform Sales Value (2021-2032) & (US$ Million)
Figure 32. Asia-Pacific Patient-Derived Disease Modeling Platform Sales Value Share by Country (%), 2025 VS 2032
Figure 33. South America Patient-Derived Disease Modeling Platform Sales Value (2021-2032) & (US$ Million)
Figure 34. South America Patient-Derived Disease Modeling Platform Sales Value Share by Country (%), 2025 VS 2032
Figure 35. Middle East & Africa Patient-Derived Disease Modeling Platform Sales Value (2021-2032) & (US$ Million)
Figure 36. Middle East & Africa Patient-Derived Disease Modeling Platform Sales Value Share by Country (%), 2025 VS 2032
Figure 37. USA Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 38. USA Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 39. USA Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 40. Canada Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 41. Canada Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 42. Canada Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 43. Mexico Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 44. Mexico Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 45. Mexico Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 46. Germany Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 47. Germany Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 48. Germany Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 49. France Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 50. France Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 51. France Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 52. U.K. Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 53. U.K. Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 54. U.K. Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 55. Italy Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 56. Italy Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 57. Italy Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 58. Spain Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 59. Spain Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 60. Spain Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 61. Russia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 62. Russia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 63. Russia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 64. Netherlands Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 65. Netherlands Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 66. Netherlands Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 67. Nordic Countries Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 68. Nordic Countries Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 69. Nordic Countries Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 70. China Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 71. China Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 72. China Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 73. Japan Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 74. Japan Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 75. Japan Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 76. South Korea Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 77. South Korea Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 78. South Korea Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 79. India Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 80. India Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 81. India Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 82. Australia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 83. Australia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 84. Australia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 85. Southeast Asia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 86. Southeast Asia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 87. Southeast Asia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 88. Brazil Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 89. Brazil Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 90. Brazil Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 91. Argentina Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 92. Argentina Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 93. Argentina Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 94. Chile Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 95. Chile Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 96. Chile Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 97. Colombia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 98. Colombia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 99. Colombia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 100. Peru Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 101. Peru Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 102. Peru Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 103. Saudi Arabia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 104. Saudi Arabia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 105. Saudi Arabia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 106. Israel Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 107. Israel Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 108. Israel Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 109. UAE Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 110. UAE Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 111. UAE Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 112. Turkey Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 113. Turkey Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 114. Turkey Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 115. Iran Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 116. Iran Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 117. Iran Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 118. Egypt Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 119. Egypt Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 120. Egypt Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 121. Years Considered
Figure 122. Research Process
Figure 123. Key Executives Interviewed
Scope & coverage.
Types
- Patient-Derived Primary Cell Models
- Patient-Derived iPSC Models
- Patient-Derived Organoid Models
- Patient-Derived Tissue Explant Models
- Patient-Derived Organ-on-a-Chip Models
- Patient-Derived Xenograft Models
Applications
- Disease Mechanism Research
- Target Discovery and Validation
- Drug Screening and Lead Optimization
- Efficacy and Resistance Evaluation
- Safety and Toxicology Assessment
- Precision Medicine and Biomarker Research
Companies covered
- Evotec
- Pharmaron
- The Jackson Laboratory
- Champions Oncology
- ATCC
- Molecular Devices
- FUJIFILM Cellular Dynamics
- REPROCELL
- Ncardia
- Axol Bioscience
- MIMETAS
- Oncodesign Services
- GemPharmatech
- Shanghai Model Organisms Center
- Medicilon
- InnoSer
- Certis Oncology Solutions
- Curi Bio
- Newcells Biotech
- K2 Oncology
- Pixlbio
- Charles River Laboratories
- Crown Bioscience
- WuXi AppTec
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Patient-Derived Disease Modeling Platform Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Patient-Derived Disease Modeling Platform Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Patient-Derived Disease Modeling Platform Market Dynamics
- 2.1 Patient-Derived Disease Modeling Platform Industry Trends
- 2.2 Patient-Derived Disease Modeling Platform Industry Drivers
- 2.3 Patient-Derived Disease Modeling Platform Industry Opportunities and Challenges
- 2.4 Patient-Derived Disease Modeling Platform Industry Restraints
3 Patient-Derived Disease Modeling Platform Market by Company
- 3.1 Global Patient-Derived Disease Modeling Platform Company Revenue Ranking in 2025
- 3.2 Global Patient-Derived Disease Modeling Platform Revenue by Company (2021-2026)
- 3.3 Global Patient-Derived Disease Modeling Platform Company Ranking (2024-2026)
- 3.4 Global Patient-Derived Disease Modeling Platform Company Manufacturing Base and Headquarters
- 3.5 Global Patient-Derived Disease Modeling Platform Company Product Type and Application
- 3.6 Global Patient-Derived Disease Modeling Platform Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Patient-Derived Disease Modeling Platform Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Patient-Derived Disease Modeling Platform Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Patient-Derived Disease Modeling Platform Market by Type
- 4.1 Patient-Derived Disease Modeling Platform Type Introduction
- 4.1.1 Patient-Derived Primary Cell Models
- 4.1.2 Patient-Derived iPSC Models
- 4.1.3 Patient-Derived Organoid Models
- 4.1.4 Patient-Derived Tissue Explant Models
- 4.1.5 Patient-Derived Organ-on-a-Chip Models
- 4.1.6 Patient-Derived Xenograft Models
- 4.2 Global Patient-Derived Disease Modeling Platform Sales Value by Type
- 4.2.1 Global Patient-Derived Disease Modeling Platform Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Patient-Derived Disease Modeling Platform Sales Value by Type (2021-2032)
- 4.2.3 Global Patient-Derived Disease Modeling Platform Sales Value Share by Type (2021-2032)
5 Patient-Derived Disease Modeling Platform Market by Application
- 5.1 Patient-Derived Disease Modeling Platform Application Introduction
- 5.1.1 Disease Mechanism Research
- 5.1.2 Target Discovery and Validation
- 5.1.3 Drug Screening and Lead Optimization
- 5.1.4 Efficacy and Resistance Evaluation
- 5.1.5 Safety and Toxicology Assessment
- 5.1.6 Precision Medicine and Biomarker Research
- 5.2 Global Patient-Derived Disease Modeling Platform Sales Value by Application
- 5.2.1 Global Patient-Derived Disease Modeling Platform Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Patient-Derived Disease Modeling Platform Sales Value by Application (2021-2032)
- 5.2.3 Global Patient-Derived Disease Modeling Platform Sales Value Share by Application (2021-2032)
6 Patient-Derived Disease Modeling Platform Regional Value Analysis
- 6.1 Global Patient-Derived Disease Modeling Platform Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Patient-Derived Disease Modeling Platform Sales Value by Region (2021-2032)
- 6.2.1 Global Patient-Derived Disease Modeling Platform Sales Value by Region: 2021-2026
- 6.2.2 Global Patient-Derived Disease Modeling Platform Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Patient-Derived Disease Modeling Platform Sales Value (2021-2032)
- 6.3.2 North America Patient-Derived Disease Modeling Platform Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Patient-Derived Disease Modeling Platform Sales Value (2021-2032)
- 6.4.2 Europe Patient-Derived Disease Modeling Platform Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Patient-Derived Disease Modeling Platform Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Patient-Derived Disease Modeling Platform Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Patient-Derived Disease Modeling Platform Sales Value (2021-2032)
- 6.6.2 South America Patient-Derived Disease Modeling Platform Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Patient-Derived Disease Modeling Platform Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Patient-Derived Disease Modeling Platform Sales Value Share by Country, 2025 VS 2032
7 Patient-Derived Disease Modeling Platform Country-level Value Analysis
- 7.1 Global Patient-Derived Disease Modeling Platform Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Patient-Derived Disease Modeling Platform Sales Value by Country (2021-2032)
- 7.2.1 Global Patient-Derived Disease Modeling Platform Sales Value by Country (2021-2026)
- 7.2.2 Global Patient-Derived Disease Modeling Platform Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.7.2 France Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.14.2 China Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.17.2 India Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Patient-Derived Disease Modeling Platform Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Patient-Derived Disease Modeling Platform Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Patient-Derived Disease Modeling Platform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Evotec
- 8.1.1 Evotec Company Information
- 8.1.2 Evotec Business Overview
- 8.1.3 Evotec Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.1.4 Evotec Patient-Derived Disease Modeling Platform Product Portfolio
- 8.1.5 Evotec Recent Developments
- 8.2 Pharmaron
- 8.2.1 Pharmaron Company Information
- 8.2.2 Pharmaron Business Overview
- 8.2.3 Pharmaron Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.2.4 Pharmaron Patient-Derived Disease Modeling Platform Product Portfolio
- 8.2.5 Pharmaron Recent Developments
- 8.3 The Jackson Laboratory
- 8.3.1 The Jackson Laboratory Company Information
- 8.3.2 The Jackson Laboratory Business Overview
- 8.3.3 The Jackson Laboratory Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.3.4 The Jackson Laboratory Patient-Derived Disease Modeling Platform Product Portfolio
- 8.3.5 The Jackson Laboratory Recent Developments
- 8.4 Champions Oncology
- 8.4.1 Champions Oncology Company Information
- 8.4.2 Champions Oncology Business Overview
- 8.4.3 Champions Oncology Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.4.4 Champions Oncology Patient-Derived Disease Modeling Platform Product Portfolio
- 8.4.5 Champions Oncology Recent Developments
- 8.5 ATCC
- 8.5.1 ATCC Company Information
- 8.5.2 ATCC Business Overview
- 8.5.3 ATCC Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.5.4 ATCC Patient-Derived Disease Modeling Platform Product Portfolio
- 8.5.5 ATCC Recent Developments
- 8.6 Molecular Devices
- 8.6.1 Molecular Devices Company Information
- 8.6.2 Molecular Devices Business Overview
- 8.6.3 Molecular Devices Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.6.4 Molecular Devices Patient-Derived Disease Modeling Platform Product Portfolio
- 8.6.5 Molecular Devices Recent Developments
- 8.7 FUJIFILM Cellular Dynamics
- 8.7.1 FUJIFILM Cellular Dynamics Company Information
- 8.7.2 FUJIFILM Cellular Dynamics Business Overview
- 8.7.3 FUJIFILM Cellular Dynamics Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.7.4 FUJIFILM Cellular Dynamics Patient-Derived Disease Modeling Platform Product Portfolio
- 8.7.5 FUJIFILM Cellular Dynamics Recent Developments
- 8.8 REPROCELL
- 8.8.1 REPROCELL Company Information
- 8.8.2 REPROCELL Business Overview
- 8.8.3 REPROCELL Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.8.4 REPROCELL Patient-Derived Disease Modeling Platform Product Portfolio
- 8.8.5 REPROCELL Recent Developments
- 8.9 Ncardia
- 8.9.1 Ncardia Company Information
- 8.9.2 Ncardia Business Overview
- 8.9.3 Ncardia Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.9.4 Ncardia Patient-Derived Disease Modeling Platform Product Portfolio
- 8.9.5 Ncardia Recent Developments
- 8.10 Axol Bioscience
- 8.10.1 Axol Bioscience Company Information
- 8.10.2 Axol Bioscience Business Overview
- 8.10.3 Axol Bioscience Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.10.4 Axol Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
- 8.10.5 Axol Bioscience Recent Developments
- 8.11 MIMETAS
- 8.11.1 MIMETAS Company Information
- 8.11.2 MIMETAS Business Overview
- 8.11.3 MIMETAS Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.11.4 MIMETAS Patient-Derived Disease Modeling Platform Product Portfolio
- 8.11.5 MIMETAS Recent Developments
- 8.12 Oncodesign Services
- 8.12.1 Oncodesign Services Company Information
- 8.12.2 Oncodesign Services Business Overview
- 8.12.3 Oncodesign Services Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.12.4 Oncodesign Services Patient-Derived Disease Modeling Platform Product Portfolio
- 8.12.5 Oncodesign Services Recent Developments
- 8.13 GemPharmatech
- 8.13.1 GemPharmatech Company Information
- 8.13.2 GemPharmatech Business Overview
- 8.13.3 GemPharmatech Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.13.4 GemPharmatech Patient-Derived Disease Modeling Platform Product Portfolio
- 8.13.5 GemPharmatech Recent Developments
- 8.14 Shanghai Model Organisms Center
- 8.14.1 Shanghai Model Organisms Center Company Information
- 8.14.2 Shanghai Model Organisms Center Business Overview
- 8.14.3 Shanghai Model Organisms Center Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.14.4 Shanghai Model Organisms Center Patient-Derived Disease Modeling Platform Product Portfolio
- 8.14.5 Shanghai Model Organisms Center Recent Developments
- 8.15 Medicilon
- 8.15.1 Medicilon Company Information
- 8.15.2 Medicilon Business Overview
- 8.15.3 Medicilon Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.15.4 Medicilon Patient-Derived Disease Modeling Platform Product Portfolio
- 8.15.5 Medicilon Recent Developments
- 8.16 InnoSer
- 8.16.1 InnoSer Company Information
- 8.16.2 InnoSer Business Overview
- 8.16.3 InnoSer Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.16.4 InnoSer Patient-Derived Disease Modeling Platform Product Portfolio
- 8.16.5 InnoSer Recent Developments
- 8.17 Certis Oncology Solutions
- 8.17.1 Certis Oncology Solutions Company Information
- 8.17.2 Certis Oncology Solutions Business Overview
- 8.17.3 Certis Oncology Solutions Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.17.4 Certis Oncology Solutions Patient-Derived Disease Modeling Platform Product Portfolio
- 8.17.5 Certis Oncology Solutions Recent Developments
- 8.18 Curi Bio
- 8.18.1 Curi Bio Company Information
- 8.18.2 Curi Bio Business Overview
- 8.18.3 Curi Bio Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.18.4 Curi Bio Patient-Derived Disease Modeling Platform Product Portfolio
- 8.18.5 Curi Bio Recent Developments
- 8.19 Newcells Biotech
- 8.19.1 Newcells Biotech Company Information
- 8.19.2 Newcells Biotech Business Overview
- 8.19.3 Newcells Biotech Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.19.4 Newcells Biotech Patient-Derived Disease Modeling Platform Product Portfolio
- 8.19.5 Newcells Biotech Recent Developments
- 8.20 K2 Oncology
- 8.20.1 K2 Oncology Company Information
- 8.20.2 K2 Oncology Business Overview
- 8.20.3 K2 Oncology Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.20.4 K2 Oncology Patient-Derived Disease Modeling Platform Product Portfolio
- 8.20.5 K2 Oncology Recent Developments
- 8.21 Pixlbio
- 8.21.1 Pixlbio Company Information
- 8.21.2 Pixlbio Business Overview
- 8.21.3 Pixlbio Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.21.4 Pixlbio Patient-Derived Disease Modeling Platform Product Portfolio
- 8.21.5 Pixlbio Recent Developments
- 8.22 Charles River Laboratories
- 8.22.1 Charles River Laboratories Company Information
- 8.22.2 Charles River Laboratories Business Overview
- 8.22.3 Charles River Laboratories Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.22.4 Charles River Laboratories Patient-Derived Disease Modeling Platform Product Portfolio
- 8.22.5 Charles River Laboratories Recent Developments
- 8.23 Crown Bioscience
- 8.23.1 Crown Bioscience Company Information
- 8.23.2 Crown Bioscience Business Overview
- 8.23.3 Crown Bioscience Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.23.4 Crown Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
- 8.23.5 Crown Bioscience Recent Developments
- 8.24 WuXi AppTec
- 8.24.1 WuXi AppTec Company Information
- 8.24.2 WuXi AppTec Business Overview
- 8.24.3 WuXi AppTec Patient-Derived Disease Modeling Platform Revenue and Gross Margin (2021-2026)
- 8.24.4 WuXi AppTec Patient-Derived Disease Modeling Platform Product Portfolio
- 8.24.5 WuXi AppTec Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst